Johnson & Johnson expects details on Covid-19 vaccine trial next week
Johnson & Johnson also forecast 2021 adjusted profit of between $9.40 and $9.60 per share after its fourth-quarter sales rose to $22.48 billion from $20.75 billion
Photo: Collected
Johnson & Johnson expects to share details on the company's late-stage Covid-19 vaccine trial early next week, Chief Executive Officer Alex Gorsky said at a post-earnings conference call on Tuesday
Data from Johnson & Johnson's single-dose Covid-19 shot was expected this month, with global hopes to battle the virus riding on multiple vaccines to ensure adequate supply.
In the latest setback to the effort, rival Merck & Co said on Monday it was discontinuing development of both its Covid-19 vaccines.
Keep updated, follow The Business Standard's Google news channel
Johnson & Johnson also forecast 2021 adjusted profit of between $9.40 and $9.60 per share after its fourth-quarter sales rose to $22.48 billion from $20.75 billion.
